Health

Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Approved for 2 Clinical Trials by CDE of NMPA

SHANGHAI, Nov. 14, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has received IND approval for two clinical studies. The first will explore its use in combination wi...

2024-11-14 22:00 414

Baijiayun Was Awarded the "2024 Future Medical Technology Leader" and Gained Another Industry Recognition

BEIJING, Nov. 14, 2024 /PRNewswire/ -- Baijiayun Group Ltd ("Baijiayun" or the "Company") (NASDAQ: RTC), a one-stop AI video solution provider, today announced it was awarded the "2024 Future Medical Technology Leader". The 2024 Future Medical Technology Conference was grandly held in Beijing. As...

2024-11-14 20:30 564

I-Mab Reports Third Quarter 2024 Results

* Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data * On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 * Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 * Estimated cash ru...

2024-11-14 20:00 485

Transforming Healthcare with Real-Time AI Image Analytic

Join us to discover how NVIDIA IGX and SDVoE enable seamless ultra-low latency solutions TAIPEI, Nov. 14, 2024 /PRNewswire/ -- Advantech announces enhanced AI detection for endoscopy surgical systems with the integration of its MIC-735M-IO, powered by NVIDIA IGX™, and the VEGA series ultra-low-l...

2024-11-14 18:37 689

Join the GenScript Biotech Global Forum in London to Navigate the Future of Cell and Gene Therapies.

PISCATAWAY, N.J., Nov. 13, 2024 /PRNewswire/ -- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments from capital markets. To strengthen this vital sector, GenScript is bringing together leading sc...

2024-11-13 23:51 775

Datasea Reports First Quarter 2025 Revenue of $21 Million, Up 206% Year-over-Year

Datasea's Top-Line Performance Driven by its Further Penetration of China's 5G AI Applications Segment BEIJING, Nov. 13, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based technology firm, today released its financial results for its first fiscal quarter...

2024-11-13 22:30 1515

Lunit Partners with VIDI Group to Deliver AI-Powered Mammography to France's Largest Radiology Network

Agreement to make Lunit INSIGHT MMG accessible to over 400 sites across France SEOUL, South Korea, Nov. 13, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a strategic alliance with VIDI Group, the lar...

2024-11-13 22:00 1255

Concord Medical Schedules 2024 Annual Meeting of Shareholders

BEIJING, Nov. 13, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it will hold its 2024 annual general meeting o...

2024-11-13 21:00 1239

XChange TEC.INC RECEIVES NASDAQ MINIMUM BID PRICE DEFICIENCY NOTICE

SHANGHAI, Nov. 12, 2024 /PRNewswire/ -- XChange TEC.INC (NASDAQ: XHG) (the "Company"), today announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") datedNovember 8, 2024 stating that the Company is not in compliance with the requirement to maintain a mi...

2024-11-13 07:00 1314

Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AI

Highlights: * ISM001-055 was safe and well-tolerated with a favorable PK profile in IPF patients * Patients who received ISM001-055 showed dose-dependent improvement in the efficacy endpoint, as measured by change in forced vital capacity (FVC) at 12 weeks CAMBRIDGE, Mass., Nov. 12, 2024 /...

2024-11-12 22:00 818

Chime Biologics and Waterstone Announce a Strategic Partnership to Empower Antibody-Drug Conjugate (ADC) Development and Manufacturing

* Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services for the global Antibody-Drug Conjugate (ADC) industry. * Chime Biologics will leverage its CMC expertise in biologics to manage Antibody Intermediate, ADC Drug Substance and Drug P...

2024-11-12 21:15 1234

2024 Tsingke High-Impact Literature Compilation - Gene Synthesis

BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke  has delivered high-quality biotechnology services and products to nearly 300,000 users globally. The number of high-level academic papers published using Tsingke's products and services has grown steadily year after year, ...

2024-11-12 18:09 881

Tsingke Successfully Showcases Innovations at BIO-Europe 2024

BEIJING, Nov. 12, 2024 /PRNewswire/ -- Tsingke proudly concluded its participation in BIO-Europe 2024, held fromNovember 4 to 6 inStockholm, Sweden. As one of the premier global events for the biotechnology, pharmaceutical, and investment sectors, over 5,500 attendees ...

2024-11-12 17:07 834

WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment

SHANGHAI, Nov. 11, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been ranked #1 in the global Life Sciences Tools & Services sector in the 2024 S&P Glo...

2024-11-12 08:00 996

HoneyNaps AI Diagnostic Medical Software as Featured in International Journal "Digital Health"

- Published clinical study on sleep apnea patients in the prestigious journal Digital Health - Clinical research on HoneyNaps SOMNUM validates its clinical efficacy BOSTON, Nov. 11, 2024 /PRNewswire/ -- Medical AI company HoneyNaps has published a paper demonstrating the clinical value and effic...

2024-11-11 22:00 801

Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.

Acquisition Strengthens Lakeside's Pharmaceutical Logistics Capabilities in China, Projected to Add US$7 Million in Annual Revenue ITASCA, Ill., Nov. 11, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based integrated cross-border supply chain s...

2024-11-11 21:45 1373

DermRays Revolutionizing At-Home Laser Hair Removal with Innovative New Products

PLEASANTON, Calif., Nov. 11, 2024 /PRNewswire/ -- As anticipation grows around  DermRays' latest developments, industry insiders are abuzz with speculation about the future direction of the company's product line. Whether through a potential upgrade to theV8S Pro

2024-11-11 21:00 713

Neurizon Therapeutics Receives Positive Opinion on Orphan Medicinal Product Designation for NUZ-001 in Europe

Highlights: * Notice of positive opinion received from the European Medicines Agency for Orphan Medicinal Product Designation for NUZ-001 in Amyotrophic Lateral Sclerosis * Orphan Designation offers 10 years of market exclusivity in Europe upon product approval, along with additional regulat...

2024-11-11 20:30 897

Professor Narayanan Parameswaran's team at Michigan State University announced that Red Ginseng is effective for intestinal health and preventing bone loss

JEJU, South Korea, Nov. 11, 2024 /PRNewswire/ -- Professor Narayanan Parameswaran's team at the Department of Physiology atMichigan State University announced the results of a study that showed that consuming red ginseng is effective for bone and intestinal health through intestinal microbiota ba...

2024-11-11 13:17 1140

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteo...

2024-11-11 08:07 1137
12345 ... 280